[6] Perol, M., E. Felip, U. Dafni, et al., Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCL...
更新8:NSCLC PD-L1表达异质性存在于肿瘤的整个诊疗阶段,选择组织进行检测时,应首选最能代表肿瘤进展的肿瘤部位,或手术标本中肿瘤组织分化最差的区域进行检测;对多个活检块/条组织推荐均应进行PD-L1检测,并重视TPS/肿瘤细胞数值最高的结果。 ...
Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chmotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data. Ann Oncol. 2022 May;33(5):511-521....
combined with PD-L1 expression, should significantly improve the response rates to immunotherapy. This would both capture patients excluded from checkpoint immunotherapy (high PD-1/PD-L1 interaction but low PD-L1 expression, 24% of patients
Tissue-based PD-L1 expression, more than any variable other than microsatellite instability-high, identified varying degrees of benefit from ICI-containing therapy vs SOC among patients with aGEC in 17 RCTs. 在17项随机对照试验中,基于组织的 PD-L1 表达比除微卫星不稳定性高以外的任何变量都更能确定...
Since PD-1 mediated the exhaustion of natural killer (NK) cell by binding to its ligand PD-L1, BMS-1 (PD-1/PD-L1 inhibitor 1) (1 μM, 3 days) is used to disturb the interaction between PD-1 and PD-L1. Dexamethasone induced increase of PD-1 expression and decrease of cytotoxicity...
英文摘要: OBJECTIVE:To ev aluate the economics of pembrolizumab versus first-line chemotherapy in the treatment of advanced non-small cell lung cancer with high programmed cell death protein ligand 1(PD-L1)expression from the perspective of Chinese healthcare system. METHODS :Published KEYNOTE- 042...
靶向PD-L1的免疫检查点抑制剂联合铂类、依托泊苷一线治疗时,患者的总生存期获得了明显的延长。但是在IMPower133试验扩展队列中入组的中国小细胞肺癌似乎没观察到生存获益。将靶向PD-1抑制剂与铂类和依托泊苷联合用于一线治疗呢?ASTRUM-005给出的答案是患者能获益,而KEYNOTE-604显示未能显著改善总生存期OS,临床试验...
PD-L1 expression was decreased in the samples from patients with AML with complete remission compared to that in patients with relapsed or refractory AML. In AML cell lines, glycolysis-associated genes ALDOA, PGK1, LDHA and HK2 were highly expressed in a PD-L1 high-expressed cell line. ...
大多数小细胞肺癌确诊的时候为广泛期小细胞肺癌(占比为80-85%),对广泛期小细胞肺癌只能以姑息治疗为主。一线铂类化疗的初始治疗应答率很高,但是中位总生存期仅有10个月,活过2年的比例不超过15%,而且无进展生存期比较短。 靶向PD-L1的免疫检查点抑制剂联合铂类、依托泊苷一线治疗时,患者的总生存期获得了明显...